Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Business Wire
Aurinia Pharmaceuticals→Kezar Life Sciences
Mar 30, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
Tracking 1 M&A deal by Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals→Kezar Life Sciences
Mar 30, 2026